Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurogene (NGNE) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Neurogene (NGNE) over the last 6 years, with Q3 2025 value amounting to $13000.0.

  • Neurogene's Gains from Investment Securities changed N/A to $13000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $42000.0, marking a year-over-year decrease of 3000.0%. This contributed to the annual value of $60000.0 for FY2024, which is 3043.48% up from last year.
  • Neurogene's Gains from Investment Securities amounted to $13000.0 in Q3 2025.
  • Over the past 5 years, Neurogene's Gains from Investment Securities peaked at $200000.0 during Q2 2023, and registered a low of $5000.0 during Q1 2023.
  • Its 3-year average for Gains from Investment Securities is $51166.7, with a median of $14500.0 in 2025.
  • Per our database at Business Quant, Neurogene's Gains from Investment Securities skyrocketed by 110000.0% in 2024 and then plummeted by 7500.0% in 2025.
  • Neurogene's Gains from Investment Securities (Quarter) stood at $200000.0 in 2023, then crashed by 70.0% to $60000.0 in 2024, then crashed by 78.33% to $13000.0 in 2025.
  • Its Gains from Investment Securities was $13000.0 in Q3 2025, compared to $14000.0 in Q2 2025 and $15000.0 in Q1 2025.